02734nam 2200625 a 450 991081723500332120240516100616.01-280-59148-X97866136213131-118-26589-01-118-26675-71-118-26679-X(CKB)2670000000175224(EBL)832587(OCoLC)787842613(SSID)ssj0000639670(PQKBManifestationID)11401942(PQKBTitleCode)TC0000639670(PQKBWorkID)10605127(PQKB)10764483(MiAaPQ)EBC832587(Au-PeEL)EBL832587(CaPaEBR)ebr10558697(CaONFJC)MIL362131(OCoLC)797824835(PPN)17900171X(EXLCZ)99267000000017522420111004d2012 uy 0engur|n|---|||||txtccrPharmaceutical lifecycle management making the most of each and every brand /Tony Ellery, Neal Hansen1st ed.Hoboken, N.J. John Wiley & Sonsc20121 online resource (413 p.)Includes index.0-470-48753-4 pt. A. Lifecycle management business environment -- pt. B. Lifecycle management regulatory and legal environment -- pt. C. Patents and exclusivities -- pt. D. Developmental LCM -- pt. E. Commercial LCM -- pt. F. Biologics and biosimilars -- pt. G. The integrated brand LCM strategy and its implementation -- pt. H. Integrating LCM with portfolio management. A comprehensive guide to optimizing the lifecycle management of pharmaceutical brands The mounting challenges posed by cost containment policies and the prevalence of generic alternatives make optimizing the lifecycle management (LCM) of brand drugs essential for pharmaceutical companies looking to maximize the value of their products. Demonstrating how different measures can be combined to create winning strategies, Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand explores this increasingly important field to help readers understand what theyPharmaceutical industryEconomic aspectsDrug approvalEconomic aspectsPharmaceutical industryEconomic aspects.Drug approvalEconomic aspects.338.4/76153Ellery Tony1624454Hansen Neal1624455MiAaPQMiAaPQMiAaPQBOOK9910817235003321Pharmaceutical lifecycle management3959431UNINA